Medical Condition News

RSS

PTSD occurs with significant frequency in civilian patients after traumatic event involving physical injury

Although most commonly associated with military combat, post-traumatic stress disorder (PTSD) can occur in civilians, too - and with consequences that are just as serious, according to a new review article in the Journal of the American Academy of Orthopaedic Surgeons (JAAOS). PTSD is a type of anxiety disorder that occurs after a person experiences a traumatic event involving physical injury, and occurs in 20 to 51 percent of patients with an orthopaedic injury.

9 May 2011

Charisela develops breakthrough adiponectin assay

Charisela Technologies, Inc., a manufacturer of advanced assays for flow cytometers, announced today that it has developed an adiponectin assay with major advantages over existing technologies, including the elimination of dilutions. Adiponectin (Acrp30), an adipocytokine, is important in many therapeutic arenas, including type 2 diabetes, obesity, atherosclerosis, and rheumatoid arthritis.

9 May 2011

Three Ontario projects set to further knowledge and discovery in biomonitoring, drug development

As part of the Genome Canada Large-Scale Applied Research Project Competition, which as a whole awarded over $58 million to 16 projects across the country, the researchers in Ontario will be focusing on biomonitoring, understanding gene function with the aim of identifying genes or proteins for drug targets, and the creation of synthetic antibodies to target cancers and other diseases.

9 May 2011

Medtronic, Bayer HealthCare expand global alliance to develop next generation diabetes management solutions

Medtronic, Inc. and Bayer HealthCare have expanded their international alliance to now include the United States and will work exclusively to develop innovative next generation diabetes management solutions for patients, state-of-the-art, wireless blood glucose meters worldwide.

From Medtronic 9 May 2011

Acousticon receives FDA clearance for ACAM-5 hearing loss product

TCG today announced that Acousticon Inc., one of its portfolio companies, recently received FDA clearance for its ACAM-5 product, allowing the company to begin US commercialization activities for the first time.

9 May 2011

Boston Scientific launches Expect Endoscopic Ultrasound Aspiration Needle

Boston Scientific Corporation today announced the U.S. and international launch of its Expect™ Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples for diagnosing and staging malignancies in organs adjacent to the gastrointestinal tract. The Expect Needle received FDA clearance and CE Mark approval earlier this year and is being marketed in the U.S., Europe and other international markets.

9 May 2011

ImThera Medical concludes Phase I and II protocols for aura6000 European Pilot study in OSA

ImThera Medical, Inc. today announced that it has concluded its Phase I and Phase II protocols for the European Pilot study of the aura6000, a neurostimulation device for treating Obstructive Sleep Apnea (OSA). Clinical trial results from the study will be announced at the American Thoracic Society's International Conference on May 16, 2011 in Denver, CO.

9 May 2011

Covidien completes enrollment in Parietex ProGrip self-fixating mesh study to treat inguinal hernias

Covidien, a leading global provider of healthcare products, today announced that all 600 patients have been enrolled in its clinical study comparing use of Parietex ProGrip self-fixating mesh to the gold-standard suture-based Lichtenstein repair method for primary inguinal hernias.

9 May 2011

KAEL-GemVax wins European telomerase patent challenge

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that the recent ruling by the European Patent Office dismissing appeals relating to Geron Corporation's European telomerase patent confirms KAEL-GemVax's patent position on lead product GV-1001, an anti-telomerase vaccine, currently completing the TeloVac Phase III trial for pancreatic cancer.

9 May 2011

OncoSec's tumor-destroying, tissue-sparing drug/device system profiled in Medical Device Daily

OncoSec Medical Inc., a therapeutic oncology company developing innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today the cancer therapy company's tumor-destroying, tissue-sparing drug/device technology was profiled in Medical Device Daily, the news source for the high-tech medical technology industry that is relied on by thousands of industry insiders every business morning.

9 May 2011

CSEW fails to protect public health by refusing to take part in variant Creutzfeldt-Jakob disease study

The creation of a post-mortem tissue archive for a study of the human form of mad cow disease failed because of a "misguided" refusal by coroners to participate.

9 May 2011

ArtVentive Medical Group performs animal studies treating target vessels with EOS device

ArtVentive Medical Group, Inc. announced today that the Company performed regulatory animal studies treating target vessels with its occlusion system - device. The procedures had a 100% success rate in terms of safety and effectiveness.

9 May 2011

Ideal psychotropic drug may cause physical dependence

A report in the current issue of Psychotherapy and Psychosomatics by a group of European investigators headed by Fabrizio Schifano has explored the potential for dependence of pregabalin using patients' online reports.

9 May 2011

Merrimack, PharmaEngine collaborate to develop and commercialize PEP02 in Asia and Europe

PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. announced today the execution of an agreement under which PharmaEngine grants back to Merrimack the rights to develop, manufacture, and commercialize PEP02 in Asia and Europe, with the exception of Taiwan.

9 May 2011

EMA agrees to Swedish Orphan Biovitrum, Biogen Idec's pediatric rFIXFc trial in hemophilia

Biogen Idec and Swedish Orphan Biovitrum today announced that the European Medicines Agency's Pediatric Committee has adopted an opinion agreeing to the pediatric investigational plan for the companies' long-lasting, fully-recombinant Factor IX Fc fusion protein.

9 May 2011

Psychotherapeutic treatment can cure cyclothymic disorder

In the current issue of Psychotherapy and Psychosomatics a group of Italian investigators headed by Giovanni Fava published a randomized controlled trial on psychotherapeutic treatment of cyclothymic disorder, a disturbance that is characterized by rapid alternation of mood swings.

9 May 2011

Epigenomics presents Septin9 blood test study data in colorectal cancer at DDW 2011

Epigenomics AG, the cancer molecular diagnostics company, reports that Dr. Uri Ladabaum, Associate Professor in the Department of Gastroenterology and Hepatology at the School of Medicine of Stanford University, has presented the results of a health economic analysis of potential future colorectal cancer screening with Septin9 blood tests at the ongoing Digestive Disease Week 2011.

9 May 2011

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.

9 May 2011

Heptares, Shire sign deal to develop novel A2A antagonist for CNS disease treatment

Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist discovered by Heptares and currently in preclinical development.

9 May 2011

Preliminary data from ST-DETECT Trial using EGM signals in ICDs presented at SCAI meeting

New data presented today at the Society for Cardiovascular Angiography and Interventions Scientific Sessions are the first to look at the use of highly specialized signals within implantable cardioverter defibrillators to detect restricted blood flow to the heart in high-risk cardiovascular disease patients outside the hospital setting.

9 May 2011

Medical Condition News

PTSD occurs with significant frequency in civilian patients after traumatic event involving physical injury

Charisela develops breakthrough adiponectin assay

Three Ontario projects set to further knowledge and discovery in biomonitoring, drug development

Medtronic, Bayer HealthCare expand global alliance to develop next generation diabetes management solutions

Acousticon receives FDA clearance for ACAM-5 hearing loss product

Boston Scientific launches Expect Endoscopic Ultrasound Aspiration Needle

ImThera Medical concludes Phase I and II protocols for aura6000 European Pilot study in OSA

Covidien completes enrollment in Parietex ProGrip self-fixating mesh study to treat inguinal hernias

KAEL-GemVax wins European telomerase patent challenge

OncoSec's tumor-destroying, tissue-sparing drug/device system profiled in Medical Device Daily

CSEW fails to protect public health by refusing to take part in variant Creutzfeldt-Jakob disease study

ArtVentive Medical Group performs animal studies treating target vessels with EOS device

Ideal psychotropic drug may cause physical dependence

Merrimack, PharmaEngine collaborate to develop and commercialize PEP02 in Asia and Europe

EMA agrees to Swedish Orphan Biovitrum, Biogen Idec's pediatric rFIXFc trial in hemophilia

Psychotherapeutic treatment can cure cyclothymic disorder

Epigenomics presents Septin9 blood test study data in colorectal cancer at DDW 2011

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Heptares, Shire sign deal to develop novel A2A antagonist for CNS disease treatment

Preliminary data from ST-DETECT Trial using EGM signals in ICDs presented at SCAI meeting

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News